Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tomokast
- Development stage
- Phase 4
- Lead developer
- RANTOMO Life Sciences Bharat
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Tomokast** is an oral fixed-dose anti-allergy tablet marketed by Rantomo Life Sciences. Each tablet contains levocetirizine 5 mg and montelukast 10 mg. Levocetirizine inhibits histamine H1 receptor signaling to reduce histamine-mediated symptoms such as sneezing, rhinorrhea, and watery eyes, while montelukast antagonizes cysteinyl leukotriene receptor 1 to reduce leukotriene-driven allergic inflammation. It is marketed for relief of allergic conditions, particularly allergic rhinitis. ([rantomo.com](https://www.rantomo.com/tomokast))
- Brand names
- Tomokast
- Other names
- levocetirizine + montelukast
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Tomokast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tomokast.